Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer

JACC: Cardiovascular Interventions

Volumn 2, Issue 4, 2009, Pages 291-299

  Byrne, Robert A ^a   Iijima, Raisuke ^a   Mehilli, Julinda ^a   Pinieck, Susanne ^a   Bruskina, Olga ^a   Schömig, Albert ^a,b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

2 year reangiography; cell proliferation drug effects; coronary restenosis; follow up studies; immunosuppressive agents therapeutic uses; polymers; stents adverse effects

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; PACLITAXEL; POLYMER; RAPAMYCIN;

AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GERMANY; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; GERMANY; HUMANS; HYPERPLASIA; LOGISTIC MODELS; MALE; MIDDLE AGED; PACLITAXEL; POLYMERS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK ASSESSMENT; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 64749101214     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.11.015     Document Type: Article

References (40)

1. Daemen J., and Serruys P.W. Drug-eluting stent update 2007: part II: unsettled issues. Circulation 116 (2007) 961-968
2. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
4. Stone G.W., Ellis S.G., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
5. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
6. Heldman A.W., Cheng L., Jenkins G.M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
7. Carter A.J., Aggarwal M., Kopia G.A., et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 (2004) 617-624
8. Wessely R., Kastrati A., and Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med 143 (2005) 392-394
9. Virmani R., Liistro F., Stankovic G., et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
10. Cosgrave J., Corbett S.J., Melzi G., et al. Late restenosis following sirolimus-eluting stent implantation. Am J Cardiol 100 (2007) 41-44
11. Serruys P.W., Luijten H.E., Beatt K.J., et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77 (1988) 361-371
12. Nobuyoshi M., Kimura T., Nosaka H., et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 12 (1988) 616-623
13. Kastrati A., Schomig A., Dietz R., Neumann F.J., and Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation 87 (1993) 1498-1505
14. Schomig A., Kastrati A., Mudra H., et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 90 (1994) 2716-2724
15. Kimura T., Yokoi H., Nakagawa Y., et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 334 (1996) 561-566
16. Hausleiter J., Kastrati A., Wessely R., et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 26 (2005) 1475-1481
17. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82 (1990) 1193-1202
18. Liistro F., Stankovic G., Di Mario C., et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 105 (2002) 1883-1886
19. Scheller B., Grandt A., Wnendt S., Lorenz G., Bohm M., and Nickenig G. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol 94 (2005) 445-452
20. Kimura T., Abe K., Shizuta S., et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105 (2002) 2986-2991
21. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
22. Finn A.V., Kolodgie F.D., Harnek J., et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
23. Luscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
24. Takano M., Ohba T., Inami S., Seimiya K., Sakai S., and Mizuno K. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J 27 (2006) 2189-2195
25. Costa M.A., and Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 111 (2005) 2257-2273
26. Aoki J., Colombo A., Dudek D., et al. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 112 (2005) 3876-3883
27. Park D.W., Hong M.K., Mintz G.S., et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT study. J Am Coll Cardiol 48 (2006) 2432-2439
28. Sousa J.E., Costa M.A., Abizaid A., et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 111 (2005) 2326-2329
29. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
30. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
31. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
32. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
33. Ellis S.G., Popma J.J., Lasala J.M., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1193-1200
34. Kereiakes D.J., Kuntz R.E., Mauri L., and Krucoff M.W. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol 45 (2005) 1206-1212
35. Mauri L., Orav E.J., O'Malley A.J., et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 111 (2005) 321-327
36. Pocock S.J., Lansky A.J., Mehran R., et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 51 (2008) 23-32
37. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
38. Mehilli J., Kastrati A., Wessely R., et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113 (2006) 273-279
39. Mehilli J., Byrne R.A., Wieczorek A., et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 29 (2008) 1975-1982
40. Windecker S., Serruys P.W., Wandel S., et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372 (2008) 1163-1173